Immuneering Corporation Profile Avatar - Palmy Investing

Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorect…

Biotechnology
US, Cambridge [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Immuneering Corporation mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of IMRX's Analysis
CIK: 1790340 CUSIP: 45254E107 ISIN: US45254E1073 LEI: - UEI: -
Secondary Listings
IMRX has no secondary listings inside our databases.